KTRA Overview

Reverse Stock Split Announcement: Kintara Therapeutics has approved a reverse stock split of its common stock at a ratio of 1-for-35, effective October 18, 2024, following the merger with TuHURA Biosciences, Inc. This will reduce the number of outstanding shares from approximately 55.6 million to about 1.6 million.

Company Transition and Focus: After the merger, Kintara will operate under the new name TuHURA Biosciences, focusing on developing innovative cancer therapies, including a personalized cancer vaccine candidate and novel antibody drug conjugates targeting immune suppression in tumors.

Reverse Stock Split Announcement: Kintara Therapeutics has approved a 1-for-35 reverse stock split of its common stock, effective October 17, 2024, coinciding with its merger with TuHURA Biosciences, which will also change its name and trading symbol to "HURA."

Company Focus and Future Plans: Following the merger, the combined company will focus on developing innovative cancer therapies, including personalized cancer vaccines and antibody drug conjugates, while maintaining a robust pipeline for treating unmet medical needs in oncology.

Correction on CVR Issuance: Kintara Therapeutics announced a correction regarding the issuance of Contingent Value Rights (CVRs) to stockholders, stating that they will be issued immediately prior to a planned reverse stock split rather than based on an earlier record date.

Merger and Stock Split Details: The proposed merger with TuHURA Biosciences is expected to close on October 18, 2024, following a reverse stock split at a ratio of 1-for-35, with stockholders receiving one CVR per share owned before the split.

Merger Announcement: Kintara Therapeutics has set a record date of October 17, 2024, for issuing Contingent Value Rights (CVRs) to its stockholders in connection with its merger with TuHURA Biosciences, expected to close on October 18, 2024, pending regulatory approval.

Reverse Stock Split: Kintara plans to implement a reverse stock split at a ratio of 1-for-35 immediately before the merger, following stockholder approval for a range of 1-for-20 to 1-for-40 during a special meeting held on October 4, 2024.

Merger Announcement: Kintara Therapeutics has received stockholder approval for its merger with TuHURA Biosciences, expected to be completed in mid-October 2024, enhancing its capabilities in cancer immunotherapy.

Financial Results: For the fiscal year ending June 30, 2024, Kintara reported a net loss of approximately $8.3 million, a significant decrease from the previous year's loss, attributed to reduced research and development expenses.

Telesis Bio Partnership Announcement: Telesis Bio, Inc. shares surged 109.9% in pre-market trading following a partnership with Beckman Coulter Life Sciences aimed at enhancing DNA and mRNA synthesis through efficient biofoundries.

Market Movements: Several stocks experienced significant pre-market trading fluctuations, with Kintara Therapeutics rising 41.8% and VS MEDIA Holdings falling 23.6%, amid various corporate announcements and financial results.